Research–led, global pharmaceutical company Glenmark Pharmaceuticals Inc., USA (Glenmark) (BSE: 532296) (NSE: GLENMARK) announced on Thursday that it has received approval from the United States Food & Drug Administration (US FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC).
The product determined by the FDA to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), of Alcon Laboratories, Inc. It is to be distributed in the United States by Glenmark Therapeutics Inc., USA. The Nielsen syndicated data for the latest 52 weeks' period ending 22 February 2025 revealed that the product achieved annual sales of approximately USD50.7m.
Marc Kikuchi, president & Business Head, North America said, 'We are pleased to continue to expand our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval